BSE Limited
P.J. Towers, DalaI Street

Mumbai - 400001

National Stock Exchange of India Ltd, Exchange Plaza, Sandra Kurla Complex, Bandra (East), Mumbai - 400051

Dear Sir/ Madam,

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Unit: Orin Laboratories Limited

With reference to the subject cited, I, Sanka Naga Jyothi belonging to promoter group, would like to bring to your notice that pursuant to scheme of Arrangement between Ortin Laboratories Limited (Demerged Company) and Vineet Laboratories Limited (Resulting Company) my holding has been changed from 90,290 Equity shares ( $0.53 \%$ ) to 43,339 Equity Shares ( $0.53 \%$ ). In this regard, I enclose herewith prescribed Form 29 (2) under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

This is for the information and records of the Exchange, please.

Thanking you.
Yours faithfully,


Sanka Naga Jyothi

Encl: As above

CC: Ortin Laboratories Limited

## Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

| 1. Name of the Target Company (TC) | Ortin Laboratories Limited |  |  |
| :--- | :--- | :--- | :--- |
| 2. Name(s) of the acquirer and Persons <br> Acting in Concert (PAC) with the <br> acquirer | Sanka Naga Jyothi |  |  |
| 3. Whether the acquirer belongs to <br> Promoter/Promoter group | Yes |  |  |
| 4. Name(s) of the Stock Exchange(s) <br> where the shares of TC are Listed | BSE Limited <br> National Stock Exchange of India Limited |  |  |
| 5etails of the acquisition / <br> disposal/holding of shares/voting <br> rights/holding of the Acquirer and <br> PAC | Number | \% w.r.t. <br> total <br> share/voti <br> ng capital <br> wherever <br> applicable | \% w.r.t. total <br> diluted <br> share/voting <br> capital of the |
| TC(*) |  |  |  |



| that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold | - | - | - |
| :---: | :---: | :---: | :---: |
| Total (a+b+c) | 46951 | 0.00 | 0.00 |
| After the disposal of shares, holding of: <br> a) Shares carrying voting rights <br> b) VRs otherwise than by shares <br> c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition. | 43339 | 0.53 | $0.53$ |
| Total ( $\mathrm{a}+\mathrm{b}+\mathrm{c}$ ) | 43339 | 0.53 | 0.53 |
| 6. Mode of sale (e.g. open market / offmarket / public issue / rights issue / preferential allotment / inter-se transfer etc). | Pursuant to Scheme of Arrangement between Ortin Laboratories Limited(Demerged Company) and Vineet Laboratories Limited (Resulting Company)sanctioned by Hon'ble National Company law Tribunal |  |  |
| 7. Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable | 23.01.2021 |  |  |
| 8. Equity share capital / total voting capital of the TC before the said acquisition / sale | 1,69,40,400 equity shares |  |  |
| 9. Equity share capital/ total voting capital of the TC after the said acquisition / sale | 81,31,392 equity shares |  |  |
| 10. Total diluted share/voting capital of the TC after the said acquisition/sale. | 81,31,392 equity shares |  |  |

$\left(^{*}\right.$ ) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


